Ardelyx (ARDX) Interest Expenses (2013 - 2026)
Ardelyx's (ARDX) quarterly Interest Expenses came in at $5.2 million in Q1 2026, up 23.0% YoY from $4.2 million in Q1 2025, and up 185.25% on a QoQ basis from -$6.0 million in Q4 2025.
Ardelyx (ARDX) Interest Expenses (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 14 years of Interest Expenses data on file, last reported at $5.2 million in Q1 2026.
- Quarterly Interest Expenses rose 23.0% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 million (down 67.95% YoY) and the FY2025 annual result came in at $219.6 million, up 5.29% from the prior year.
- Interest Expenses climbed to $5.2 million in Q1 2026, from -$6.0 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $6.2 million in Q4 2024 to a low of -$6.0 million in Q4 2025.
- A 5-year average of $1.7 million and a median of $1.1 million in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2024 — Interest Expenses jumped 571.65% — and 2025, when it plunged 197.44%.
- Tracing ARDX's Interest Expenses over 5 years: stood at -$293000.0 in 2022, then jumped by 415.36% to $924000.0 in 2023, then jumped by 571.65% to $6.2 million in 2024, then sank by 197.44% to -$6.0 million in 2025, then jumped by 185.25% to $5.2 million in 2026.
- The last three Interest Expenses figures came in at $5.2 million (Q1 2026), -$6.0 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | 4.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.96 Mn |
| Jun 30, 2026 | 4.96 Mn |
| Mar 31, 2026 | 5.16 Mn |
| Mar 31, 2026 | 5.16 Mn |
| Dec 31, 2025 | -6.05 Mn |
| Dec 31, 2025 | -6.05 Mn |
| Sep 30, 2025 | 2.19 Mn |
| Sep 30, 2025 | 2.19 Mn |
| Jun 30, 2025 | 1.84 Mn |
| Jun 30, 2025 | 1.84 Mn |
| Mar 31, 2025 | 4.19 Mn |
| Mar 31, 2025 | 4.19 Mn |
| Dec 31, 2024 | 6.21 Mn |
| Dec 31, 2024 | 6.21 Mn |
| Sep 30, 2024 | 3.36 Mn |
| Sep 30, 2024 | 3.36 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Mar 31, 2024 | 2.10 Mn |
| Mar 31, 2024 | 2.10 Mn |